arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Aptevo Therapeutics Inc.

APVO
$1.87 ▼ -0.02 (-1.06%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aptevo Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -151.4% ↗
FCF / Share $-81.11
Trailing P/E —
Price / Book 0.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.11M
↓ -74.7% —
Net Income Profit after all expenses
$-25.97M
↓ -7.6% —
Operating Margin Operating profit as % of sales
-174.1%
↓ -32.5% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
5
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 45 quarters